SSRIs ease children’s OCD symptoms but rarely deliver a complete recovery alone

A review of trials involving more than 600 young people suggests SSRIs can improve obsessive-compulsive symptoms and nearly double treatment response, but work best alongside realistic expectations and, where possible, exposure-based therapy.

Parents and clinicians often hope an SSRI will wipe out a child’s obsessive-compulsive disorder. A new review suggests the reality is more modest: these medicines can help, but they usually do not produce a dramatic or complete recovery on their own. The latest discussion from the Carlat Psychiatry Podcast centred on a 2025 meta-analysis that pooled four randomised controlled trials involving more than 600 children and adolescents aged six to 18 with OCD, and the message was that medication can ease symptoms without being a cure.

The analysis used the Children’s Yale-Brown Obsessive Compulsive Scale, the standard measure for tracking symptom severity in paediatric OCD. On that scale, SSRIs beat placebo by about three points on average, which points to a statistically meaningful but limited improvement. The podcast’s hosts noted that this kind of result can sound underwhelming compared with families’ hopes, yet it still matters clinically because the medications nearly doubled the chance of a treatment response, usually defined as a symptom drop of at least 35%.

Severity at the start of treatment appeared to shape outcomes. Children with milder OCD were more likely to benefit, while those with more severe symptoms were less likely to reach a full response. Each one-point increase in baseline severity was linked with roughly an 8% fall in the odds of response. Age, sex, weight and how long the illness had lasted did not seem to change the result in any important way. The study did not suggest that SSRIs are useless in harder cases; rather, they appear more likely to take the edge off than to bring symptoms down to nothing.

That fits with older research. A 2016 meta-analysis indexed on PubMed found that SSRIs and clomipramine were both better than placebo in paediatric OCD, with clomipramine showing a larger benefit, while earlier reviews described SSRI effects as small but real. A Cochrane review of medication for childhood anxiety disorders, including OCD, also found that drug treatment reduced symptoms overall, though tolerability was worse than placebo. Taken together, the evidence supports SSRIs as a reasonable option, but not as a stand-alone answer for every child.

The practical implication is familiar to child psychiatrists: for mild OCD, cognitive behavioural therapy with exposure and response prevention remains the preferred starting point, while medication alone can still be reasonable when therapy is unavailable or a family strongly prefers it. For more severe illness, SSRIs are usually best understood as one part of a combined plan. The podcast also stressed the need for careful follow-up, since these medicines can cause activation, sleep disruption and, rarely, suicidal thinking, even though they more often help than harm when monitored properly. For families, the key message is not that SSRIs fail, but that they usually work best when expectations are realistic and treatment is built around more than one tool.